124 related articles for article (PubMed ID: 9193736)
21. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
22. beta-Endorphin, cortisol, and prolactin in serum of schizophrenic patients during long-term neuroleptic treatment and after withdrawal: relationships to psychopathology.
Naber D; Albus M; Muller F; Burke H; Welter D; Ackenheil M; Hippius H
Psychopharmacol Bull; 1982 Oct; 18(4):224-6. PubMed ID: 6130563
[No Abstract] [Full Text] [Related]
23. Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects.
Kahn RS; Siever LJ; Gabriel S; Amin F; Stern RG; DuMont K; Apter S; Davidson M
Psychiatry Res; 1992 Jul; 43(1):1-12. PubMed ID: 1332094
[TBL] [Abstract][Full Text] [Related]
24. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
[TBL] [Abstract][Full Text] [Related]
25. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.
Mueller EA; Murphy DL; Sunderland T
J Clin Endocrinol Metab; 1985 Dec; 61(6):1179-84. PubMed ID: 4055985
[TBL] [Abstract][Full Text] [Related]
26. Serotonin receptor responsivity in schizophrenia.
Kahn RS; Davidson M
Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():47-51. PubMed ID: 7911140
[No Abstract] [Full Text] [Related]
27. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
Anand A; Charney DS; Delgado PL; McDougle CJ; Heninger GR; Price LH
Am J Psychiatry; 1994 Nov; 151(11):1626-30. PubMed ID: 7943451
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.
Abel KM; O'Keane V; Murray RM
Br J Psychiatry; 1996 Jan; 168(1):57-60. PubMed ID: 8770429
[TBL] [Abstract][Full Text] [Related]
29. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood.
Riedel WJ; Klaassen T; Griez E; Honig A; Menheere PP; van Praag HM
Neuropsychopharmacology; 2002 Mar; 26(3):358-67. PubMed ID: 11850150
[TBL] [Abstract][Full Text] [Related]
30. [Psychopharmacologic approaches to schizophrenic psychoses].
Giacardy-Paty M; Soubrouillard C; Blin O
Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
[TBL] [Abstract][Full Text] [Related]
31. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo.
Pallanti S; Bernardi S; Quercioli L; DeCaria C; Hollander E
CNS Spectr; 2006 Dec; 11(12):956-64. PubMed ID: 17146409
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction.
Lerer B; Ran A; Blacker M; Silver H; Weller MP; Drummer D; Ebstein B; Calev A
Schizophr Res; 1988; 1(6):405-10. PubMed ID: 3154528
[TBL] [Abstract][Full Text] [Related]
33. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers.
Maes M; Meltzer HY
Psychiatry Res; 1996 Oct; 64(3):147-59. PubMed ID: 8944393
[TBL] [Abstract][Full Text] [Related]
34. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia.
Seibyl JP
J Psychopharmacol; 1997; 11(2):188-9. PubMed ID: 9208382
[No Abstract] [Full Text] [Related]
35. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
Rapaport MH; Wolkowitz O; Kelsoe JR; Pato C; Konicki PE; Pickar D
Neuropsychopharmacology; 1993 Sep; 9(2):111-5. PubMed ID: 8105790
[TBL] [Abstract][Full Text] [Related]
36. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia.
Scheepers FE; Gespen de Wied CC; Kahn RS
J Clin Psychopharmacol; 2001 Dec; 21(6):575-82. PubMed ID: 11763004
[TBL] [Abstract][Full Text] [Related]
37. Serotonin function and treatment response to clozapine in schizophrenic patients.
Kahn RS; Davidson M; Siever L; Gabriel S; Apter S; Davis KL
Am J Psychiatry; 1993 Sep; 150(9):1337-42. PubMed ID: 8394651
[TBL] [Abstract][Full Text] [Related]
38. Responses to mCPP stimulation in depressed patients.
Thakore JH
Am J Psychiatry; 1995 Dec; 152(12):1833-4; author reply 1834-5. PubMed ID: 8526261
[No Abstract] [Full Text] [Related]
39. Studies of serotonin function in anorexia nervosa.
Brewerton TD; Jimerson DC
Psychiatry Res; 1996 Apr; 62(1):31-42. PubMed ID: 8739113
[TBL] [Abstract][Full Text] [Related]
40. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
